Mumbai-headquartered pharmaceutical manufacturer running two formulation plants — in Daman and Selaqui (Dehradun, Uttarakhand) — under a single reportable pharmaceuticals segment.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 112 | 133 | 152 | 151 | 174 | 198 | 210 | 206 |
| Borrowings | 6 | 6 | 6 | 0 | 0 | 4 | 1 | 4 |
| Other Liabilities | 23 | 25 | 28 | 20 | 28 | 25 | 19 | 27 |
| Total Liabilities | 144 | 168 | 190 | 174 | 206 | 229 | 233 | 241 |
| AssetsFixed Assets | 23 | 21 | 24 | 25 | 24 | 23 | 24 | 44 |
| CWIP | 0 | 0 | 2 | 0 | 0 | 2 | 14 | 0 |
| Investments | 25 | 33 | 46 | 41 | 50 | 52 | 57 | 46 |
| Other Assets | 97 | 112 | 118 | 108 | 132 | 152 | 138 | 150 |
| Total Assets | 144 | 168 | 190 | 174 | 206 | 229 | 233 | 241 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -1 | -4 | 1 | 6 | 13 | -5 | -1 | 16 |
| Cash from Investing | 3 | -2 | 0 | -6 | -3 | 1 | 0 | -18 |
| Cash from Financing | -1 | 4 | 0 | 0 | -6 | 0 | 3 | 0 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -4 | -5 | 0 | 1 | 11 | -6 | -4 | -5 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (11.2×) and current (12.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 36.4% growth and a 11× exit, ₹550 only delivers your return if you pay ₹1,150. The price is currently baking in 19% growth.
EPS grows 36.4%/yr for 5 years, then fades to 6% over 2, exits at 11×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 36.4% | 62.54 |
| FY28 | 36.4% | 85.30 |
| FY29 | 36.4% | 116.35 |
| FY30 | 36.4% | 158.71 |
| FY31 | 36.4% | 216.48 |
| FY32 | 21.2% ·fade | 262.37 |
| FY33 | 6.0% ·fade | 278.11 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.